Comments: Advance Notice of Proposed Rulemaking: Medicare Program; International Pricing Index Model for Medicare Part B Drugs
December 31, 2018
Comments
We appreciate the Centers for Medicare & Medicaid Services (CMS) releasing this Advance Notice of Proposed Rulemaking (ANPRM) which contains thoughtful explorations of the causes of high drug spending in Medicare Part B drug coverage. CMS acknowledges that Medicare and its beneficiaries pay more for their drugs in general than other countries do and that the increase in Medicare drug spending over the past five years is largely due to increases in the manufacturer prices of drugs and mix of drugs for those beneficiaries who received them rather than increases in Medicare enrollment and drug utilization. We support the goal of finding mechanisms to bring down the cost of Part B medications for both Medicare beneficiaries and the Medicare program as a whole.
Any changes to the Medicare program must aim for healthier people, better care, and smarter spending—not paying more for less. As policymakers debate the future of health care, we will provide our insights here.
Thinking ahead to Medicare's future, it’s important to modernize benefits and pursue changes that improve how people with Medicare navigate their coverage on a daily basis. Here are our evolving 30 policy goals for Medicare’s future.
You can help protect and strengthen Medicare by taking action on the important issues we are following, subscribe to newsletter alerts, or follow along on social media. Any way you choose to get involved is a contribution that we appreciate greatly.
Comments: Advance Notice of Proposed Rulemaking: Medicare Program; International Pricing Index Model for Medicare Part B Drugs
We appreciate the Centers for Medicare & Medicaid Services (CMS) releasing this Advance Notice of Proposed Rulemaking (ANPRM) which contains thoughtful explorations of the causes of high drug spending in Medicare Part B drug coverage. CMS acknowledges that Medicare and its beneficiaries pay more for their drugs in general than other countries do and that the increase in Medicare drug spending over the past five years is largely due to increases in the manufacturer prices of drugs and mix of drugs for those beneficiaries who received them rather than increases in Medicare enrollment and drug utilization. We support the goal of finding mechanisms to bring down the cost of Part B medications for both Medicare beneficiaries and the Medicare program as a whole.
Reference
Recent Documents
Comments on 2024 Physician Fee Schedule
Comments on the Short-Term, Limited-Duration Insurance Proposed Rule
Comments on Health and Human Services Grants Regulation
Increasing Access to Medicare Savings Programs: Lessons Learned and Policy Recommendations from New York
Comparing Original Medicare and Medicare Advantage
Medicare Advantage History: Legislative Milestones
Any changes to the Medicare program must aim for healthier people, better care, and smarter spending—not paying more for less. As policymakers debate the future of health care, we will provide our insights here.
Thinking ahead to Medicare's future, it’s important to modernize benefits and pursue changes that improve how people with Medicare navigate their coverage on a daily basis. Here are our evolving 30 policy goals for Medicare’s future.
You can help protect and strengthen Medicare by taking action on the important issues we are following, subscribe to newsletter alerts, or follow along on social media. Any way you choose to get involved is a contribution that we appreciate greatly.